Clinical trials have demonstrated weight loss ranging from approximately 10% with GLP-1 agents at weight management doses (e.g., semaglutide 2.4 mg in the STEP trials) to over 20% with tirzepatide at higher doses (SURMOUNT trials)
For most people, these GI effects are manageable with dietary adjustments
25 Hypoglycemia risk can be minimized with appropriate titration and glycemic control during the first weeks (8 to 16) following insulin initiation, as well as by using basal insulinsparticularly longer-acting basal insulins
Diabetes is a chronic disease caused by the pancreas not producing enough insulin or not being able to effectively use the insulin it produces
I try and eat as many colorful vegetables and salads as possible
6a, b, TG treatment markedly reduced mRNA expression of collegan II, and upregulated the mRNA levels of MMP3